PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22106763-3	2011	This study is to evaluate the usefulness of fluorine-18-fluorodeoxyglucose (FDG)-PET in assessing the therapeutic response of Donepezil to DAT using Regions of Interest (ROI) analysis.	Fluorodeoxyglucose F18	44-74	solute carrier family 6 member 3	Homo sapiens	139-142	
31273436-4	2019	In addition, the specific association of striatal DaT binding with cortical limbic and associative metabolic activity was evaluated by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in PD-ICD patients and investigated using statistical parametric mapping (SPM8).	Fluorodeoxyglucose F18	135-157	solute carrier family 6 member 3	Homo sapiens	50-53	
31273436-4	2019	In addition, the specific association of striatal DaT binding with cortical limbic and associative metabolic activity was evaluated by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in PD-ICD patients and investigated using statistical parametric mapping (SPM8).	Fluorodeoxyglucose F18	159-162	solute carrier family 6 member 3	Homo sapiens	50-53	
31273436-7	2019	Lower DaT availability in the VS was associated with lower FDG uptake in several cortical areas belonging to the limbic and associative circuits, and in other regions involved in reward and inhibition processes (p < 0.0001 uncorrected; k > 50 voxels).	Fluorodeoxyglucose F18	59-62	solute carrier family 6 member 3	Homo sapiens	6-9	
22106763-3	2011	This study is to evaluate the usefulness of fluorine-18-fluorodeoxyglucose (FDG)-PET in assessing the therapeutic response of Donepezil to DAT using Regions of Interest (ROI) analysis.	Fluorodeoxyglucose F18	76-79	solute carrier family 6 member 3	Homo sapiens	139-142	
19142633-10	2009	CONCLUSION: Progressive CMRglc reductions on FDG-PET occur years in advance of clinical DAT symptoms in patients with pathologically verified disease.	Fluorodeoxyglucose F18	45-48	solute carrier family 6 member 3	Homo sapiens	88-91	
34728939-1	2021	Aim: To elucidate the patterns of characteristic hypometabolism on 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in multisystem atrophy (MSA) and their correlation with the patterns of uptake on dopamine transporter imaging with 99mTc TRODAT-1 SPECT.	Fluorodeoxyglucose F18	67-90	solute carrier family 6 member 3	Homo sapiens	241-261	
34728939-1	2021	Aim: To elucidate the patterns of characteristic hypometabolism on 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in multisystem atrophy (MSA) and their correlation with the patterns of uptake on dopamine transporter imaging with 99mTc TRODAT-1 SPECT.	Fluorodeoxyglucose F18	92-99	solute carrier family 6 member 3	Homo sapiens	241-261